Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission?

被引：2
|
作者：
Turner, D. [1 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Crusaid Kobler AIDS Ctr,Infect Dis Unit, IL-69978 Tel Aviv, Israel
来源：
HIV MEDICINE | 2011年 / 12卷 / 04期
关键词：
INFECTION; VARIANTS;
D O I：
10.1111/j.1468-1293.2010.00883.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：193 / 194
页数：2
相关论文
共 50 条
  • [41] Diminished representation of HIV-1 variants containing protease associated mutations and M184V in reverse transcriptase (RT) in primary HIV-1 infection
    Wainberg, MA
    Brenner, B
    Routy, JP
    Moisi, D
    Roger, M
    Turner, D
    MICROBIOLOGICA, 2004, 27 (02): : 145 - 145
  • [42] Implications of lamivudine use and the M184V mutation in V118I-related multidrug resistance
    Brenner, BG
    Oliveira, M
    Micheli, V
    Moisi, D
    Cargnel, A
    Petrella, M
    Wainberg, MA
    ANTIVIRAL THERAPY, 2003, 8 (03) : U133 - U134
  • [43] Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
    Perez-Valero, Ignacio
    Llibre, Josep M.
    Castagna, Antonella
    Pulido, Federico
    Molina, Jean-Michel
    Esser, Stefan
    Margot, Nicolas
    Shao, Yongwu
    Temme, Lauren
    Piontkowsky, David
    McNicholl, Ian R.
    Haubrich, Richard
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 490 - 495
  • [44] The H208Y mutations in reverse transcriptase is significantly associated with NRTI-exposure, M184V and TAM1 mutation pathways
    Geretti, A. M.
    Sabin, C.
    Dunn, D.
    ANTIVIRAL THERAPY, 2006, 11 (05) : S158 - S158
  • [45] Effects of M184V mutation in multi-dideoxynucleoside analog resistant HIV-1 reverse transcriptase on removal of β-D-dioxolane-guanine monophosphate from blocked primer
    Lennerstrand, J
    Espili, NH
    Pavlova, A
    Chu, CK
    Asif, G
    Schinazi, RF
    ANTIVIRAL THERAPY, 2005, 10 : S79 - S79
  • [46] Effects of M184V mutation in multi-dideoxynucleoside analog resistant HIV-1 reverse transcriptase on removal of β-D-dioxolane-guanine monophosphate from blocked primer
    Lennerstrand, J
    Espili, NH
    Pavlova, A
    Chu, CK
    Asif, G
    Schinazi, RF
    ANTIVIRAL THERAPY, 2005, 10 (04) : S79 - S79
  • [47] Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Zaccarelli, M
    Perno, CF
    Forbici, F
    Cingolani, A
    Liuzzi, G
    Bertoli, A
    Trotto, MP
    Bellocchi, MC
    Di Giambenedetto, S
    Tozzi, V
    Gori, C
    D'Arrigo, R
    De Longis, P
    Noto, P
    Girardi, E
    De Luca, A
    Antinori, A
    ANTIVIRAL THERAPY, 2003, 8 (01) : 51 - 56
  • [48] Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxyfluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase
    Ray, AS
    Murakami, E
    Peterson, CN
    Shi, JX
    Schinazi, RF
    Anderson, KS
    ANTIVIRAL RESEARCH, 2002, 56 (03) : 189 - 205
  • [49] Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase
    Bradshaw, D.
    Malik, S.
    Booth, C.
    Van Houtte, M.
    Pattery, T.
    Waters, A.
    Ainsworth, J.
    Geretti, A. M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4489 - 4491
  • [50] Is Atripla a feasible switch option in patients with an existing M184V mutation?
    Rockwood, N.
    Singh, G. Jagjit
    Nelson, M.
    HIV MEDICINE, 2011, 12 : 29 - 29
12345